Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout

Kyle Blankenship

Merck’s proposed buyout of Acceleron Pharma represents a major bolt-on opportunity as the drugmaker looks to a future without megablockbuster Keytruda driving sales. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout

Kyle Blankenship

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Versant's latest biotech focuses on inflammatory diseases

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Avoro Cap­i­tal, the deal killer be­hind the Seagen-Im­munomedics blowup, has turned its eyes on Mer­ck­'s Ac­celeron buy­out

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Avoro Capital, the deal killer behind the Seagen-Immunomedics blowup, has turned its eyes on Merck's Acceleron buyout